Vyome Holdings (HIND) Shares Outstanding (2017 - 2026)
Vyome Holdings (HIND) posted quarterly Shares Outstanding (Entity) of $7.0 million for Q1 2026, up 36046.3% year-over-year from N/an in Q1 2025, and up 224.73% quarter-over-quarter from $2.2 million in Q4 2025.
Vyome Holdings (HIND) Shares Outstanding (2017 - 2026) Analysis & Trends
Vyome Holdings' Shares Outstanding (Entity) history runs 10 years deep, the most recent figure standing at $7.0 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 36046.3% year-over-year to $7.0 million; the TTM figure through Mar 2026 stood at $7.0 million (up 36046.3% YoY), while the FY2025 annual figure was $2.2 million, up 41818.97% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $7.0 million, up from $2.2 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $7.0 million in Q1 2026, with the low at $64.0 in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $4044.0 (2024), against an average of $721889.2.
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) surged 69.77% in 2022, then jumped 54104.95% in 2025.
- Vyome Holdings' Shares Outstanding (Entity) stood at $73.0 in 2022, then soared by 1306.85% to $1027.0 in 2023, then jumped by 402.04% to $5156.0 in 2024, then soared by 41818.97% to $2.2 million in 2025, then soared by 224.73% to $7.0 million in 2026.
- Business Quant data shows HIND's Shares Outstanding (Entity) at $7.0 million in Q1 2026, $2.2 million in Q4 2025, and $2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 | 7.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.69 Mn |
| Mar 31, 2026 | 6.69 Mn |
| Dec 31, 2025 | 2.16 Mn |
| Sep 30, 2025 | 2.76 Mn |
| Jun 30, 2025 | 292,190.00 |
| Mar 31, 2025 | 19,417.00 |
| Dec 31, 2024 | 5,156.00 |
| Sep 30, 2024 | 5,089.00 |
| Jun 30, 2024 | 4,348.00 |
| Mar 31, 2024 | 4,044.00 |
| Dec 31, 2023 | 1,027.00 |
| Sep 30, 2023 | 595.00 |
| Jun 30, 2023 | 560.00 |
| Mar 31, 2023 | 294.00 |
| Dec 31, 2022 | 73.00 |
| Sep 30, 2022 | 78.00 |
| Jun 30, 2022 | 67.00 |
| Mar 31, 2022 | 64.00 |
| Dec 31, 2021 | 43.00 |
| Sep 30, 2021 | 41.00 |